American Association for Cancer Research
Browse
10780432ccr132750-sup-fig4.pdf (62.26 kB)

Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Download (62.26 kB)
journal contribution
posted on 2023-03-31, 17:42 authored by Gilles Manceau, Sandrine Imbeaud, Raphaële Thiébaut, François Liébaert, Karine Fontaine, Francis Rousseau, Bérengère Génin, Delphine Le Corre, Audrey Didelot, Marc Vincent, Jean-Baptiste Bachet, Benoist Chibaudel, Olivier Bouché, Bruno Landi, Frédéric Bibeau, Karen Leroy, Frédérique Penault-Llorca, Jean-Luc Van Laethem, Pieter Demetter, Sabine Tejpar, Simona Rossi, Neda Mosakhani, Pia Österlund, Raija Ristamäki, Virinder Sarhadi, Sakari Knuutila, Valérie Boige, Thierry André, Pierre Laurent-Puig

PDF file - 62KB, Kaplan-Meier PFS according to level of expression of hsa-miR-31-3p in the whole series of 132 patients. For the 102 patients who were NRAS wild-type based on Sanger sequencing of exon 2 and 3, the hazard ratio was 2.51 CI95 percent (1.6-4) and the median progression free survival was 10.14 and 35.71 weeks respectively for the high and low risk groups.

History

ARTICLE ABSTRACT

Purpose: To identify microRNAs (miRNA) that predict response to anti-EGFR antibodies in patients with wild-type KRAS metastatic colorectal cancer (mCRC).Experimental Design: miRNA profiling was performed in a training set of 87 patients with mCRC refractory to chemotherapy treated with anti-EGFR antibodies. This included 33 fresh-frozen (FF) and 35 formalin-fixed paraffin-embedded (FFPE) samples retrospectively collected and 19 prospectively collected FF samples. An independent validation cohort consisting of 19 FF and 26 FFPE prospectively collected samples from patients with mCRC treated with anti-EGFR antibodies was used to confirm our findings.Results: After screening the expression of 1,145 miRNAs in FF samples from the training set, we identified that hsa-miR-31-3p expression level was significantly associated with progression-free survival (PFS). Statistical models based on miRNA expression discriminated between high and low risk of progression for both FF and FFPE samples. These models were confirmed in the validation cohort for both FF [HR, 4.1; 95% confidence interval (CI), 1.1–15.3; P < 0.04] and FFPE samples (HR, 2.44; 95% CI, 1.1–5.4; P = 0.028). The percentage of variation of RECIST criteria in the validation series was significantly associated with the expression level of hsa-miR-31-3p (r2 = 0.49; P = 0.0035) and risk status determined by hsa-miR-31-3p expression level (P = 0.02, Kruskal–Wallis rank test). Nomograms were built and validated to predict PFS-depending on hsa-miR-31-3p expression level. Following in vitro studies, we identified 47 genes regulated by hsa-miR-31-3p.Conclusion: Hsa-miR-31-3p seems to be a new mCRC biomarker whose expression level allows for the identification of patients with wild-type KRAS mCRC who are more likely to respond to anti-EGFR therapy. Clin Cancer Res; 20(12); 3338–47. ©2014 AACR.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC